SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy
French Biotech Tackling Retinitis Pigmentosa
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
You may also be interested in...
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.